BELKIN Vision logo — BELKIN Vision is now part of Alcon. Follow Alcon for more up...

BELKIN Vision

BELKIN Vision is now part of Alcon. Follow Alcon for more updates.

Founded 2013 Israel Israel 20 employees Grant Total: $36.35M Health Care, Medical Devices

General Information

Company Name BELKIN Vision
Founded Year 2013
Location Israel Israel
Founders / Decision Makers
Team member
Employees 20
Industries Health Care, Medical Devices
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with BELKIN Vision. To contact BELKIN Vision, visit belkin-vision.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About BELKIN Vision

BELKIN Vision is making waves in the health care industry with its innovative approach to glaucoma laser therapy. The company's slogan, "Accessible First-Line Glaucoma Care for All," captures its mission of providing accessible and efficient treatment for glaucoma. Founded in 2013 and headquartered in Israel, BELKIN Vision has developed the BELKIN Vision Eagle™, an efficient, non-contact, and automated glaucoma laser therapy device that is now available for sale in the EU and the UK. The company's recent Venture Round investment at 20 December 2021 saw participation from The European Innovation Council, signaling confidence in the company's vision and technology. With its focus on expanding access to glaucoma treatment, BELKIN Vision is poised to make a significant impact on ophthalmology. For further inquiries, contact [email protected].

Taxonomy: Glaucoma laser therapy, Ophthalmology technology, Medical device innovation, Selective laser trabeculoplasty, Accessible healthcare, Global healthcare, Non-invasive treatment, Ophthalmic innovation, Patient-friendly technology, Healthcare accessibility, Laser treatment revolution, Eye care technology, Innovative medical devices, Global health disparity, Ophthalmic care revolution

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €17.50M 1
European Innovation Council
20 Dec 2021
Venture Round Undisclosed 1
European Innovation Council
20 Dec 2021
Series B $12.25M 5
Rimonci Capital, Santen Ventures +3
21 Jul 2020
Series A $6.60M 3
European Union, ZICOM Holdings +1
05 Jun 2017

BELKIN Vision Alternatives & Competitors

View All Alternatives
BELKIN Vision vs

Ultrasound Cyclo Plasty = Focused, Adaptable, Proven

Series D
25 employees
Health Care, Medical Devices
BELKIN Vision vs
Alievio
Alievio United States

Developing the first personalized glaucoma treatment to stop vision loss.

Series A
4 employees
Health Care, Medical Devices
BELKIN Vision vs
Myra Vision
Myra Vision United States

a Shifamed Portfolio Company

Series B
24 employees
Health Care, Medical Devices

FAQ About BELKIN Vision

BELKIN Vision is now part of Alcon. Follow Alcon for more updates.
BELKIN Vision was founded in 2013.
BELKIN Vision is headquartered in Israel.
BELKIN Vision operates in Health Care and Medical Devices. Its work centres on Glaucoma laser therapy, Ophthalmology technology, Medical device innovation and Selective laser trabeculoplasty.
BELKIN Vision has approximately 20 employees.
BELKIN Vision has completed 4 funding rounds, raising a total of $36.35M. The latest funding stage is Grant.
Top alternatives and competitors to BELKIN Vision include EYETECHCARE, Alievio, Myra Vision, Rheon Medical, Refocus Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BELKIN Vision and EYETECHCARE are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BELKIN Vision, https://bouncewatch.com/company/belkin-vision, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes